Skip to main content

Clinical Trials Using Glofitamab

Review the clinical trials studying glofitamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Status: Active
Location: 13 locations
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Status: Active
Location: 13 locations
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 11 locations
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Status: Active
Location: 13 locations
Obinutuzumab, Glofitamab and Lenalidomide for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with a BTK Inhibitor
Status: Active
Location: 10 locations
Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial
Status: Active
Location: 7 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations
Glofitamab and Obinutuzumab with or without Polatuzumab Vedotin, Pirtobrutinib or Atezolizumab for the Treatment Richter's Transformation
Status: Active
Location: 5 locations
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Active
Location: 6 locations
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 5 locations
Glofitamab plus Polatuzumab-R-CHP for the Treatment of High-Risk Diffuse Large B-Cell Lymphoma
Status: Active
Location: 4 locations
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Status: Active
Location: 4 locations
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
Glofitamab with Pirtobrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: 3 locations
Mosunetuzumab or Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphoma After Receiving CAR T-cell Therapy
Status: Active
Location: 2 locations
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Status: Active
Location: 3 locations
Glofitamab with Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients with Newly Diagnosed High Risk Mantle Cell Lymphoma
Status: Active
Location: 2 locations
Testing the Anti-cancer Drug, Glofitamab, in Patients with Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned after CAR-T Cell Therapy
Status: Active
Location: JHU Sidney Kimmel Comprehensive Cancer Center LAO, Baltimore, Maryland
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Glofitamab and Axicabtagene Ciloleucel as Second-Line Treatment for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Glofitamab Plus Ibrutinib with Obinutuzumab for the Treatment of Patients with Mantle Cell Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Glofitamab with Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington